Phase II study of carboplatin, irinotecan and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

BACKGROUND: We evaluated the efficacy of carboplatin, irinotecan and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial. METHODS: Eligible patients received carboplatin (area under the plasma curve [AUC] 4...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Reardon, David A., Desjardins, Annick, Peters, Katherine B., Vredenburgh, James J., Gururangan, Sridharan, Sampson, John H., McLendon, Roger E., Herndon, James E., Coan, April, Threatt, Stevie, Friedman, Allan H., Friedman, Henry S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3158844/
https://ncbi.nlm.nih.gov/pubmed/21590689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26188
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller